SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    André J Scheen, A review of gliptins for 2014, Expert Opinion on Pharmacotherapy, 2015, 16, 1, 43

    CrossRef

  2. 2
    HL Katzeff, D Williams-Herman, L Xu, G Golm, H Wang, Q Dong, JR Johnson, EA O’Neill, KD Kaufman, SS Engel, BJ Goldstein, Long-term Efficacy of Sitagliptin as Either Monotherapy or Add-on Therapy to Metformin: Improvement in Glycemic Control Over 2 Years in Patients with Type 2 Diabetes, Current Medical Research & Opinion, 2015, 1

    CrossRef

  3. 3
    S. Chon, J.-P. Riveline, B. Blondeau, J.-F. Gautier, Incretin-based therapy and pancreatic beta cells, Diabetes & Metabolism, 2014, 40, 6, 411

    CrossRef

  4. 4
    Ronald Goldenberg, Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review, Current Medical Research and Opinion, 2014, 30, 3, 431

    CrossRef

  5. You have free access to this content5
    W. M. Valencia, H. Florez, Pharmacological treatment of diabetes in older people, Diabetes, Obesity and Metabolism, 2014, 16, 12
  6. 6
    D. H. Van Raalte, R. E. van Genugten, B. Eliasson, D. L. Moller-Goede, A. Mari, A. Tura, C. Wilson, P. Fleck, M. R. Taskinen, U. Smith, M. Diamant, The effect of alogliptin and pioglitazone combination therapy on various aspects of  -cell function in patients with recent-onset type 2 diabetes, European Journal of Endocrinology, 2014, 170, 4, 565

    CrossRef

  7. 7
    Richard B. Silverman, Mark W. Holladay, The Organic Chemistry of Drug Design and Drug Action, 2014,

    CrossRef

  8. 8
    Benjamin Szlyk, Craig R Braun, Sanda Ljubicic, Elaura Patton, Gregory H Bird, Mayowa A Osundiji, Franz M Matschinsky, Loren D Walensky, Nika N Danial, A phospho-BAD BH3 helix activates glucokinase by a mechanism distinct from that of allosteric activators, Nature Structural & Molecular Biology, 2013, 21, 1, 36

    CrossRef

  9. 9
    Richard I. G. Holt, A review of reviews: a virtual issue, Diabetes, Obesity and Metabolism, 2013, 15, 1
  10. 10
    André J. Scheen, Cardiovascular effects of gliptins, Nature Reviews Cardiology, 2013, 10, 2, 73

    CrossRef

  11. 11
    Sang Ah Lee, DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes, The Journal of Korean Diabetes, 2013, 14, 3, 128

    CrossRef

  12. 12
    Avivit Cahn, Itamar Raz, Emerging gliptins for type 2 diabetes, Expert Opinion on Emerging Drugs, 2013, 18, 2, 245

    CrossRef

  13. 13
    R. E. van Genugten, D. L. Möller-Goede, D. H. van Raalte, M. Diamant, Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes, Diabetes, Obesity and Metabolism, 2013, 15, 7
  14. 14
    Erin D Roe, Natalie C Pon, Priscilla Hollander, Philip Raskin, The ‘collateral benefits‘ of noninsulin therapies for Type 2 diabetes, Diabetes Management, 2013, 3, 2, 145

    CrossRef

  15. 15
    Matthew P. Coghlan, David Fairman, Introduction to Biological and Small Molecule Drug Research and Development, 2013,

    CrossRef

  16. 16
    Michaela Diamant, Choosing a blood-glucose-lowering agent after metformin, The Lancet, 2012, 379, 9833, 2220

    CrossRef

  17. 17
    Larry K. Golightly, Caitlin C. Drayna, Michael T. McDermott, Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors, Clinical Pharmacokinetics, 2012, 51, 8, 501

    CrossRef

  18. 18
    Larry K. Golightly, Caitlin C. Drayna, Michael T. McDermott, Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors, Clinical Pharmacokinetics, 2012, 51, 8, 501

    CrossRef

  19. 19
    Chrysi Koliaki, John Doupis, Linagliptin/Metformin Fixed-Dose Combination Treatment: A Dual Attack to Type 2 Diabetes Pathophysiology, Advances in Therapy, 2012, 29, 12, 993

    CrossRef

  20. 20
    M. R. Rizzo, M. Barbieri, R. Marfella, G. Paolisso, Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition, Diabetes Care, 2012, 35, 10, 2076

    CrossRef

  21. 21
    A. Pocai, Unraveling oxyntomodulin, GLP1's enigmatic brother, Journal of Endocrinology, 2012, 215, 3, 335

    CrossRef